Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:CLNN NASDAQ:KTTA NASDAQ:MCRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$3.07+4.1%$2.70$1.58▼$11.99$72.79M0.92108,845 shs38,985 shsCLNNClene$6.60-18.4%$5.68$2.28▼$13.50$77.75M0.89363,570 shs1.27 million shsKTTAPasithea Therapeutics$0.85+0.4%$0.77$0.28▼$3.79$21.20M0.22353,825 shs452,479 shsMCRBSeres Therapeutics$7.44-3.3%$8.69$6.53▼$29.98$71.66M0.1262,522 shs109,273 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics0.00%+5.26%+20.97%-38.40%-71.51%CLNNClene0.00%+1.32%+19.92%+43.79%+106.04%KTTAPasithea Therapeutics0.00%+21.88%+9.23%+0.12%-39.93%MCRBSeres Therapeutics0.00%+3.96%-17.91%-50.58%-20.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$3.07+4.1%$2.70$1.58▼$11.99$72.79M0.92108,845 shs38,985 shsCLNNClene$6.60-18.4%$5.68$2.28▼$13.50$77.75M0.89363,570 shs1.27 million shsKTTAPasithea Therapeutics$0.85+0.4%$0.77$0.28▼$3.79$21.20M0.22353,825 shs452,479 shsMCRBSeres Therapeutics$7.44-3.3%$8.69$6.53▼$29.98$71.66M0.1262,522 shs109,273 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics0.00%+5.26%+20.97%-38.40%-71.51%CLNNClene0.00%+1.32%+19.92%+43.79%+106.04%KTTAPasithea Therapeutics0.00%+21.88%+9.23%+0.12%-39.93%MCRBSeres Therapeutics0.00%+3.96%-17.91%-50.58%-20.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 2.33Hold$17.50470.03% UpsideCLNNClene 2.67Moderate Buy$33.25403.79% UpsideKTTAPasithea Therapeutics 1.67Reduce$3.00252.98% UpsideMCRBSeres Therapeutics 2.00Hold$14.0088.17% UpsideCurrent Analyst Ratings BreakdownLatest KTTA, CLNN, ACTU, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026CLNNClene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.005/4/2026CLNNClene D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.004/22/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.004/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/13/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.004/2/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026ACTUActuate Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/13/2026CLNNClene Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.34 per shareN/ACLNNClene$200K388.74N/AN/A($1.62) per share-4.07KTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/AMCRBSeres Therapeutics$789K90.83$1.06 per share7.00$4.89 per share1.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$22.23M-$1.05N/AN/AN/AN/A-799.68%-205.80%N/ACLNNClene-$26.17M-$2.60N/AN/AN/A-13,086.50%N/A-135.77%5/6/2026 (Estimated)KTTAPasithea Therapeutics-$20.43M-$3.57N/AN/AN/AN/A-85.48%-77.42%5/21/2026 (Estimated)MCRBSeres Therapeutics$5.70M$0.6611.27N/AN/AN/A-111.10%-32.28%5/5/2026 (Estimated)Latest KTTA, CLNN, ACTU, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026N/AKTTAPasithea Therapeutics-$0.45N/AN/AN/A$0.10 millionN/A5/6/2026Q1 2026CLNNClene-$0.6217N/AN/AN/A$0.05 millionN/A5/5/2026Q1 2026MCRBSeres Therapeutics-$1.88-$2.08-$0.20-$2.08$0.41 million$0.36 million3/30/2026Q4 2025KTTAPasithea Therapeutics-$0.18-$0.89-$0.71-$0.89$0.10 millionN/A3/26/2026Q4 2025ACTUActuate Therapeutics-$0.24-$0.18+$0.06-$0.18N/AN/A3/12/2026Q4 2025CLNNClene-$0.74-$0.88-$0.14-$0.88$0.03 million$0.08 million3/12/2026Status updateMCRBSeres Therapeutics-$2.39-$1.89+$0.50-$1.76N/A$0.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A2.392.39CLNNCleneN/A0.830.83KTTAPasithea TherapeuticsN/A11.3511.35MCRBSeres TherapeuticsN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ACLNNClene23.28%KTTAPasithea Therapeutics23.92%MCRBSeres Therapeutics59.34%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics57.98%CLNNClene28.30%KTTAPasithea Therapeutics2.00%MCRBSeres Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1023.71 million9.96 millionN/ACLNNClene10011.78 million8.45 millionNo DataKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionableMCRBSeres Therapeutics3309.63 million9.18 millionOptionableKTTA, CLNN, ACTU, and MCRB HeadlinesRecent News About These CompaniesSeres Therapeutics (NASDAQ:MCRB) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPSMay 5 at 11:46 AM | marketbeat.comSeres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 5 at 7:00 AM | globenewswire.comSeres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for ...May 4 at 12:00 AM | finance.yahoo.comSeres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel DiseaseMay 4 at 7:00 AM | globenewswire.comSeres Therapeutics (MCRB) Projected to Post Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Pass Below 200 Day Moving Average - Here's What HappenedApril 22, 2026 | marketbeat.comSeres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026April 20, 2026 | globenewswire.comSeres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026April 20, 2026 | globenewswire.comSeres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average - Here's What HappenedApril 11, 2026 | marketbeat.comSeres Therapeutics to Present at CARB-X Investor DayApril 9, 2026 | globenewswire.comWhy Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 5.41%March 23, 2026 | aaii.comASeres Therapeutics: Q4 Earnings SnapshotMarch 12, 2026 | khou.comKSeres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 12, 2026 | globenewswire.comSeres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks TranscriptMarch 3, 2026 | seekingalpha.comSeres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business UpdatesMarch 2, 2026 | globenewswire.comSeres stock falls after pausing Phase 2 study and cutting workforce by 30%February 12, 2026 | in.investing.comMCRB stock declines as Seres Therapeutics pauses SER-155 phase 2 study and shrinks headcount by 30%February 12, 2026 | msn.comWhy Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 28.96%February 12, 2026 | aaii.comA5MCRB : Seres Therapeutics Pauses Key Drug Study, Cuts Jobs...February 12, 2026 | benzinga.comSeres down after pausing investments for lead programFebruary 12, 2026 | seekingalpha.comSeres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune DiseasesFebruary 12, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAI, Satellites and Staples: Insiders Are Buying and Selling 3 Big NamesBy Leo Miller | April 13, 2026Intel's New Orbit: From Chip Lag to Leading EdgeBy Jeffrey Neal Johnson | April 8, 20263 Under-the-Radar Tech Names Investors Might Have MissedBy Nathan Reiff | April 11, 2026The New Nokia: A Bullish Upgrade Ignites This Big AI Bet By Jeffrey Neal Johnson | April 16, 2026Rocket Lab Is Back at a Line in the Sand—Now What? By Ryan Hasson | April 16, 2026KTTA, CLNN, ACTU, and MCRB Company DescriptionsActuate Therapeutics NASDAQ:ACTU$3.07 +0.12 (+4.07%) Closing price 04:00 PM EasternExtended Trading$3.08 +0.01 (+0.16%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Clene NASDAQ:CLNN$6.60 -1.49 (-18.42%) Closing price 04:00 PM EasternExtended Trading$6.68 +0.08 (+1.14%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Pasithea Therapeutics NASDAQ:KTTA$0.85 +0.00 (+0.39%) Closing price 04:00 PM EasternExtended Trading$0.85 +0.00 (+0.01%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Seres Therapeutics NASDAQ:MCRB$7.44 -0.25 (-3.25%) Closing price 04:00 PM EasternExtended Trading$7.42 -0.03 (-0.34%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
